Chemokines: Agents for the immunotherapy of cancer?

Nature Reviews Immunology

Volumn 2, Issue 3, 2002, Pages 175-184

  Homey, Bernhard ^a   Müller, Anja ^a   Zlotnik, Albert ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Eos Biotechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CCL20 CHEMOKINE; CD40 LIGAND; CHEMOKINE; CHEMOKINE RECEPTOR; CXCL15 CHEMOKINE; CXCL9 CHEMOKINE; FLT3 LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 2; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TUMOR VACCINE; UNCLASSIFIED DRUG; XCL1 CHEMOKINE; CYTOKINE;

ACTIN POLYMERIZATION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CELL SUBPOPULATION; CELL TRANSPORT; CLINICAL TRIAL; CPG ISLAND; DENDRITIC CELL; DNA MICROARRAY; DRUG EFFICACY; GENE EXPRESSION; GENE TRANSFER; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKOCYTE MIGRATION; MEMORY CELL; METASTASIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; VACCINATION; ANIMAL; IMMUNOTHERAPY; NEOPLASM; PHYSIOLOGY;

ANIMALS; CHEMOKINES; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS;

EID: 0142166426     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri748     Document Type: Review

References (86)

1. Butcher, E. C. & Picker, L. J. Lymphocyte homing and homeostasis. Science 272, 60-66 (1996).
2. Homey, B. & Zlotnik, A. Chemokines in allergy. Curr. Opin. Immunol. 11, 626-634 (1999).
3. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127 (2000). Introduces the new systematic classification for chemokines and describes their role in immunity.
4. Caux, C. et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol. 22, 345-369 (2000). Describes chemokine receptor expression of distinct dendritic cell subsets, and their responsiveness and role in dendritic cell transport.
5. Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23-33 (1999).
6. Homey, B. et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J. Immunol. 164, 3465-3470 (2000).
7. Morales, J. et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl Acad. Sci. USA 96, 14470-14475 (1999).
8. Campbell, J. J. et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400, 776-780 (1999).
9. + T cells activated in cutaneous or mucosal lymphoid tissues. J. Exp. Med. 195, 136-141 (2002).
10. + T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 165, 6590-6598 (2000).
11. Taub, D. D., Sayers, T. J., Carter, C. R. & Ortaldo, J. R. α and β chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155, 3877-3888 (1995).
12. + T cells. J. Immunol. 167, 3064-3073 (2001).
13. Bernardini, G. et al. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood 96, 4039-4045 (2000).
14. Gupta, S. K., Lysko, P. G., Pillarisetti, K., Ohlstein, E. & Stadel, J. M. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem. 273, 4282-4287 (1998).
15. Salcedo, R. et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am. J. Pathol. 154, 1125-1135 (1999).
16. + endothelial cells. J. Immunol. 166, 7571-7578 (2001).
17. Kleeff, J. et al. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81, 650-657 (1999).
18. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
19. Scotton, C. J., Wilson, J. L., Milliken, D., Stamp, G. & Balkwill, F. R. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61, 4961-4965 (2001). References 18 and 19 show that tumour cells express functionally active chemokine receptors on their cell surface and provide evidence for the role for chemokine receptors in tumour cell migration and metastasis.
20. Schadendorf, D. et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 151, 2667-2675 (1993).
21. Miyamoto, M. et al. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells. Cancer Immunol. Immunother. 47, 47-57 (1998).
22. Brew, R. et al. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12, 78-85 (2000).
23. Venkatakrishnan, G., Salgia, R. & Groopman, J. E. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J. Biol. Chem. 275, 6868-6875 (2000).
24. Balentien, E., Mufson, B. E., Shattuck, R. L., Derynck, R. & Richmond, A. Effects of MGSA/GROα on melanocyte transformation. Oncogene 6, 1115-1124 (1991).
25. Owen, J. D. et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine β and γ proteins. Int. J. Cancer 73, 94-103 (1997).
26. Arenberg, D. A. et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102, 465-472 (1998).
27. Ahuja, S. K. & Murphy, P. M. The CXC chemokines growth-regulated oncogene (GRO)α, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 271, 20545-20550 (1996).
28. Belperio, J. A. et al. CXC chemokines in angiogenesis. J. Leukoc. Biol. 68, 1-8 (2000).
29. Strieter, R. M. et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348-27357 (1995).
30. Inoue, K. et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874-4884 (2000).
31. Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D. & Fidler, I. J. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54, 3242-3247 (1994).
32. Singh, R. K., Varney, M. L., Bucana, C. D. & Johansson, S. L. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res. 9, 383-387 (1999).
33. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
34. Zeelenberg, I. S., Ruuls-Van Stalle, L. & Roos, E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma. J. Clin. Invest. 108, 269-277 (2001).
35. Murphy, P. M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345, 833-835 (2001).
36. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
37. Asher, A. L. et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146, 3227-3234 (1991).
38. Tahara, H. et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54, 182-189 (1994).
39. Wang, J. M., Shen, W., Chertov, O., van Damme, J. & Oppenheimer, J. J. in Chemokines and Cancer (ed. Rollins, B. J.) 129-141 (Humana, Totowa, New Jersey, 1999).
40. Laning, J., Kawasaki, H., Tanaka, E., Luo, Y. & Dorf, M. E. Inhibition of in vivo tumor growth by the β chemokine, TCA3. J. Immunol. 153, 4625-4635 (1994).
41. Hirose, K. et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br. J. Cancer 72, 708-714 (1995).
42. Nakashima, E. et al. A candidate for cancer gene therapy: MIP-1α gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm. Res. 13, 1896-1901 (1996).
43. Mule, J. J. et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7, 1545-1553 (1996).
44. Giovarelli, M. et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164, 3200-3206 (2000).
45. Braun, S. E. et al. The CC chemokine CK β-11/MIP-3 β/ELC/ Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. 164, 4025-4031 (2000).
46. Fushimi, T., Kojima, A., Moore, M. A. & Crystal, R. G. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105, 1383-1393 (2000).
47. Kirk, C. J. et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61, 2062-2070 (2001). Shows the efficacy of chemokine (CCL21)-transfected dendritic cells to induce the recruitment of leukocytes in vivo and to mediate the induction of antitumour Immunity.
48. Sharma, S. et al. Secondary lymphoid tissue chemokine mediates T-cell-dependent antitumor responses in vivo. J. Immunol. 164, 4558-4563 (2000).
49. Vicari, A. P. et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165, 1992-2000 (2000).
50. Luster, A. D. & Leder, P. IP-10, a-C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178, 1057-1065 (1993).
51. + T cells and neutrophils expressing XCR1 receptor. J. Immunol. 167, 57-65 (2001).
52. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998). Reviews recent findings using dendritic-cell-based immunotherapy and gives an outlook for future directions.
53. Greten, T. F. & Jaffee, E. M. Cancer vaccines. J. Clin. Oncol. 17, 1047-1060 (1999).
54. Banchereau, J., Schuler-Thurner, B., Palucka, A. K. & Schuler, G. Dendritic cells as vectors for therapy. Cell 106, 271-274 (2001).
55. Nagira, M. et al. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. Eur. J. Immunol. 28, 1516-1523 (1998).
56. - NK cells and late stage lymphoid progenitors. Cell. Immunol. 193, 226-235 (1999).
57. Hedrick, J. A. & Zlotnik, A. Identification and characterization of a novel βchemokine containing six conserved cysteines. J. Immunol. 159, 1589-1593 (1997).
58. Kelner G. S. et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 266, 1395-1399 (1994).
59. Kennedy, J. et al. Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 155, 203-209 (1995).
60. Cao, X. et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161, 6238-6244 (1998).
61. Dilloo, D. et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med. 2, 1090-1095 (1996).
62. Emtage, P. C. et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10, 697-709 (1999).
63. Ma, X., Aste-Amezaga, M., Gri, G., Gerosa, F. & Trinchieri, G. Immunomodulatory functions and molecular regulation of IL-12. Chem. Immunol. 68, 1-22 (1997).
64. Trinchieri, G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243 (1998).
65. Voest, E. E. et al. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586 (1995).
66. Narvaiza, I. et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164, 3112-3122 (2000).
67. Palmer, K., Hitt, M., Emtage, P. C., Gyorffy, S. & Gauldie, J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8, 282-290 (2001).
68. Ruehlmann, J. M. et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61, 8498-8503 (2001).
69. Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. & Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Bictechnol. 17, 253-258 (1999). Shows the efficacy of fusion proteins that combines a chemokine with tumour antigen to attract leukocytes in vivo and to induce protective antitumour immunity.
70. Tazi, A. et al. Evidence that granulocyte-macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J. Clin. Invest. 91, 566-576 (1993).
71. Maas, R. A., Dullens, H. F. & Den Otter, W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141-148 (1993).
72. Nomura, T., Hasegawa, H., Kohno, M., Sasaki, M. & Fujita, S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1α chemokine genes. Int. J. Cancer 91, 597-606 (2001). Describes the enhanced efficacy of combining chemokines together with both T-cell (IL-2)- and dendritic-cell (GM-CSF)-activating cytokines for the immunotherapy of experimental tumours.
73. Morse, M. A., Clay, T. M., Hobeika, A. C., Mosca, P. J. & Lyerly, H. K. Surrogate markers of response to cancer immunotherapy. Expert Opin. Biol. Ther. 1, 153-158 (2001).
74. Glennie, M. J. & Johnson, P. W. Clinical trials of antibody therapy. Immunol. Today 21, 403-410 (2000).
75. Harjunpaa, A., Junnikkala, S. & Meri, S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51, 634-641 (2000).
76. Agha-Mohammadi, S. & Lotze, M. T. Regulatable systems: applications in gene therapy and replicating viruses. J. Clin. Invest. 105, 1177-1183 (2000).
77. Kirkwood, J. M. et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18, 2444-2458 (2000).
78. Jager, D., Jager, E. & Knuth, A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54, 669-674 (2001).
79. Ockert, D., Schmitz, M., Hampl, M. & Rieber, E. P. Advances in cancer immunotherapy. Immunol. Today 20, 63-65 (1999).
80. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001). The authors review the links between cancer and inflammation. They propose that the inflammatory cells and cytokines that are found in tumours contribute to tumour growth, progression and immunosuppression, rather than to mount an effective host antitumour response.
81. Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339-1346 (2001).
82. Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545-1552 (2000).
83. Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309-314 (2000).
84. Bottazzi, B., Walter, S., Govoni, D., Colotta, F. & Mantovani, A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148, 1280-1285 (1992).
85. Huang, S. et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol. Immunother. 39, 231-238 (1994).
86. Nakashima, E. et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res. 12, 1598-1604 (1995).